HepaRegeniX GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.heparegenix.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Safety of HRX215 in Patients After Minor and Major Liver Resection
Phase 1
Recruiting
- Conditions
- Colorectal Liver MetastasesLiver Resection
- Interventions
- Drug: HRX215 capsulesDrug: Placebo capsules
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- HepaRegeniX GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT06638502
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
News
No news found